- Report
- May 2025
- 188 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 185 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- April 2025
- 105 Pages
Global
From €5329EUR$5,950USD£4,543GBP
- Report
- April 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- June 2025
- 402 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- May 2025
- 87 Pages
Global
From €3500EUR$4,186USD£3,088GBP
- Report
- April 2024
- 88 Pages
Global
From €3500EUR$4,186USD£3,088GBP
- Report
- January 2024
- 77 Pages
Global
From €3500EUR$4,186USD£3,088GBP
- Report
- June 2025
- 50 Pages
Global
From €2374EUR$2,650USD£2,023GBP
- Report
- October 2024
Global
From €3135EUR$3,500USD£2,672GBP

Tobramycin is an aminoglycoside antibiotic used to treat a variety of bacterial infections. It is commonly used to treat respiratory tract infections, urinary tract infections, and skin and soft tissue infections. Tobramycin is also used to treat certain types of meningitis and sepsis. It is usually administered intravenously or intramuscularly, and is available in both generic and branded forms.
Tobramycin is a widely used antibiotic, and is often used in combination with other antibiotics to treat more serious infections. It is generally well tolerated, with few side effects. However, it can cause nephrotoxicity and ototoxicity, and should be used with caution in patients with renal impairment.
The tobramycin market is highly competitive, with a number of companies offering branded and generic versions of the drug. Some of the major players in the market include Pfizer, Merck, Novartis, Sanofi, and Mylan. Show Less Read more